NDRA logo

NDRA
ENDRA Life Sciences Inc

11,054
Mkt Cap
$6.87M
Volume
12,296.00
52W High
$11.96
52W Low
$2.90
PE Ratio
-0.45
NDRA Fundamentals
Price
$5.99
Prev Close
$5.89
Open
$5.91
50D MA
$5.79
Beta
1.42
Avg. Volume
68,109.47
EPS (Annual)
-$56.94
P/B
27.50
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
ENDRA Feasibility Study Demonstrates TAEUS Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
ENDRA Life Sciences Inc. (NASDAQ: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease...
Business Wire·13d ago
News Placeholder
More News
News Placeholder
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease...
Business Wire·16d ago
News Placeholder
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...
Business Wire·20d ago
News Placeholder
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...
Business Wire·1mo ago
News Placeholder
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
Zacks·2mo ago
News Placeholder
What’s Driving The Rally In NDRA Stock Today?
The company announced $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors to be used to launch a digital asset treasury strategy.
Stocktwits·2mo ago
News Placeholder
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Zacks·2mo ago
News Placeholder
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...
Business Wire·2mo ago
News Placeholder
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the three and nine months ended September 30, 2024 and provided...
Business Wire·1y ago
News Placeholder
Study Highlighting ENDRA Life Sciences TAEUS Technology in Patients with High BMI to be Presented at AASLDs The Liver Meeting 2024
ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS), today announced the acceptance of a poster titled Noninvasive assessment of steatotic liver...
Business Wire·1y ago

Latest NDRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.